Helix Acquisition Corp. II appoints Albert A. Holman, III to its Board of Directors

BridgeBio Oncology Therapeutics, Inc.

Albert A. Holman, III appointed on Feb 8, 2025 as Class III independent director.
Holman brings life sciences investment banking experience; will serve on Audit Committee.
Sponsor transferred 30,000 Class B ordinary shares to Holman in connection with appointment.
Holman executed standard SPAC Letter Agreement and Joinder to Registration Rights Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.